Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Proceedings Article
  • Published:

Chronic lymphocytic leukemia: treatment of relapse

Leukemia Supplements volume 1, pages S31–S32 (2012)Cite this article

Abstract

Despite significant advances in the frontline treatment of chronic lymphocytic leukemia (CLL), patients eventually experience disease progression. Treatment selection of relapsed disease depends upon a variety of factors, including patient age, performance status, duration of response to initial therapy, type of prior therapy, disease-related manifestations and genetic abnormalities within the CLL cells. This presentation offers synthetic overview of the options in this field.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK . Unmutated Ig vh genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848–1854.

    Article  CAS  Google Scholar 

  2. Damnle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840–1847.

    Article  Google Scholar 

  3. Crespo M, Bosh F, Villamor N, Bellosillo B, Colomer D, Rozman M et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003; 348: 1764–1775.

    CAS  Google Scholar 

  4. Dohner H, Fischer K, Bentz M, Hansen K, Benner A, Cabot G et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995; 85: 1580–1589.

    Article  CAS  Google Scholar 

  5. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O’Brien S et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990–4997.

    Article  CAS  Google Scholar 

  6. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111: 5446–5456.

    Article  CAS  Google Scholar 

  7. Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd L et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1750–1757.

    Article  CAS  Google Scholar 

  8. Hallek M . State-of-the-art treatment of chronic lymphocytic leukemia. Hematol Am Soc Hematol Educ Program 2009, 440–449.

  9. Osterborg A, Foa R, Bezares RF, Dearden C, Dyer MJ, Geisler C et al. Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia. Leukemia 2009; 23: 1980–1988.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Onco-Hematology, Division of Hematology, Niguarda Ca’ Granda Hospital, Milano, Italy

    M Montillo

Authors
  1. M Montillo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M Montillo.

Ethics declarations

Competing interests

MM received lecture fees from the Genzyme Corporation, GlaxoSmithKline plc and F. Hoffmann-La Roche Ltd, and grant research support from GlaxoSmithKline plc and Hospira Inc.

Additional information

This article was published as part of a supplement that was supported by Novartis, MSD Italia, Roche, Celgene, GlaxoSmithKline, Sanofi, Gilead, Adienne, Italfarmaco, Pierre Fabre Pharmaceuticals with an unrestricted educational contribution to AREO-Associazione Ricerche Emato-Oncologiche (Genoa) and AMS—Associazione Malattie del Sangue (Milan) for the purpose of advancing research in acute and chronic leukemia.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Montillo, M. Chronic lymphocytic leukemia: treatment of relapse. Leukemia Suppl 1 (Suppl 2), S31–S32 (2012). https://doi.org/10.1038/leusup.2012.18

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leusup.2012.18

Keywords

Search

Advanced search

Quick links